S-adenosyl-L-methionine for Treatment of Depression, Osteoarthritis, and Liver Disease

Published in: Evidence Report/Technology Assessment No. 64 (Prepared by Southern California/RAND Evidence-Based Practice Center, under Contract No. 290-97-0001). AHRQ Publication No. 02-E033. (Rockville, MD: Agency for Healthcare Research and Quality, Oct. 2002), 5 p

Posted on RAND.org on December 31, 2001

by Mary L. Hardy, Ian D. Coulter, Joya T. Favreau, Sally C. Morton, Swamy R. Venuturupalli, Francesco Chiapelli, Frederico Rossi, Greg Orshansky, Lara Hilton, Beth Roth, Marika Booth, Paul G. Shekelle

Read More

Access further information on this document at www.ahrq.gov

This article was published outside of RAND. The full text of the article can be found at the link above.

Clinical Focus What study reports were available on the use of SAMe for depression, ostheoarthritis, and liver disease? What types of outcomes were measured for the identified conditions? How did results for treatment with SAMe compare to placebo and conventional pharmacology? What non-English language publications on SAMe treatment are available and accessible? What is the methodological quality of the studies identified? Can results be pooled to allow a risk ratio and an effect size for SAMe to be calculated

Research conducted by

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.